DZ1926A1 - Formulations pharmaceutiques. - Google Patents

Formulations pharmaceutiques.

Info

Publication number
DZ1926A1
DZ1926A1 DZ950107A DZ950107A DZ1926A1 DZ 1926 A1 DZ1926 A1 DZ 1926A1 DZ 950107 A DZ950107 A DZ 950107A DZ 950107 A DZ950107 A DZ 950107A DZ 1926 A1 DZ1926 A1 DZ 1926A1
Authority
DZ
Algeria
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
DZ950107A
Other languages
English (en)
Original Assignee
Smithkline Beckman P L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9417953A external-priority patent/GB9417953D0/en
Priority claimed from GBGB9503752.9A external-priority patent/GB9503752D0/en
Application filed by Smithkline Beckman P L C filed Critical Smithkline Beckman P L C
Application granted granted Critical
Publication of DZ1926A1 publication Critical patent/DZ1926A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DZ950107A 1994-09-03 1995-08-02 Formulations pharmaceutiques. DZ1926A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9417953A GB9417953D0 (en) 1994-09-03 1994-09-03 Pharmaceutical formulations
GBGB9503752.9A GB9503752D0 (en) 1995-02-24 1995-02-24 Pharmaceutical formulations
US46044195A 1995-06-02 1995-06-02

Publications (1)

Publication Number Publication Date
DZ1926A1 true DZ1926A1 (fr) 2002-02-17

Family

ID=27267365

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ950107A DZ1926A1 (fr) 1994-09-03 1995-08-02 Formulations pharmaceutiques.

Country Status (8)

Country Link
EP (1) EP0782443A1 (fr)
JP (1) JPH10505595A (fr)
AU (1) AU3471995A (fr)
DZ (1) DZ1926A1 (fr)
IL (1) IL115125A0 (fr)
MA (1) MA23663A1 (fr)
TR (1) TR199501082A2 (fr)
WO (1) WO1996007408A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004510A1 (es) 1995-09-07 1998-12-16 Smithkline Beecham Plc Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
DE69815833T2 (de) * 1997-02-14 2004-05-19 Laboratoire Glaxosmithkline S.A.S. Amoxicillin und clavulanat enthaltende arzneizubereitungen
US6706290B1 (en) 1998-07-06 2004-03-16 Olvai E. Kajander Methods for eradication of nanobacteria
WO2000001238A1 (fr) * 1998-07-06 2000-01-13 Kajander E Olavi Procedes relatifs a l'elimination des nanobacteries
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (fr) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Nouvelle formulation
US8614315B2 (en) * 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
WO2011152809A2 (fr) * 2010-06-03 2011-12-08 Bilgic Mahmut Formulations effervescentes comprenant de la céphalosporine et de l'acide clavulcanique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002312B1 (fr) * 1977-11-26 1982-02-03 Beecham Group Plc Dérivés de l'acide clavulanique et compositions pharmaceutiques les contenant
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE69425131T2 (de) * 1993-01-22 2001-03-15 Smithkline Beecham Plc Verwendung von clavulansäure und einem antibiotikum zur behandlung von infektionen

Also Published As

Publication number Publication date
WO1996007408A1 (fr) 1996-03-14
IL115125A0 (en) 1995-12-31
JPH10505595A (ja) 1998-06-02
AU3471995A (en) 1996-03-27
EP0782443A1 (fr) 1997-07-09
TR199501082A2 (tr) 1996-06-21
MA23663A1 (fr) 1996-04-01

Similar Documents

Publication Publication Date Title
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
TR199901077A3 (tr) Ispençiyari formülasyonlar.
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
DE69530325D1 (de) Aerosol-arzneiformulierungen
FI971279A (fi) Lääkkeitä
DE69525148T2 (de) Pharmazeutische formulierung
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
ID24654A (id) Formulasi farmasi omeprazola
NO981008D0 (no) Farmasöytisk formulering
DZ1559A1 (fr) Compositions pharmaceutiques.
DZ1926A1 (fr) Formulations pharmaceutiques.
ID16781A (id) Formulasi-formulasi farmasi
ITMI941169A0 (it) Formulazioni farmaceutiche
BR9507768A (pt) Composição farmacêutica
MX9200532A (es) Agente farmaceuticos.
FI973230A (fi) Uusi farmaseuttinen formulaatio
MA26604A1 (fr) Compositions pharmaceutiques.
FI951155A0 (fi) Farmaseuttinen valmiste
FI923371A (fi) En farmaceutisk formulation.
TR199601018A1 (tr) Farmasötik bilesikler.
DZ2159A1 (fr) Produits pharmaceutiques.
NL1004386A1 (nl) Mondverzorgingsmiddel.
SE9404467D0 (sv) Drug formulations